Discovery and characterization of QTX3544, a potent, selective, and orally bioavailable allosteric G12V preferring multi KRAS inhibitor

被引：0
|
作者：
Zhang, Yang W.
Vo, Elizabeth Donohue
Gan, Pei
Rominger, Dave
Silva, Jillian M.
Zhang, Yang J.
Pan, Christopher
Lee, Greg
Micozzi, John M.
Ben Reid
McDonough, Brooke
Sinha, Arghyotri
Hospital, Audrey
Krauth, Doug
Luengo, Juan I.
Kramer, Mike
Pitt, Cameron
Lin, Hong
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-LB163
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB163
引用
收藏
页数：2
相关论文
共 28 条
  • [1] Discovery and characterization of QTX3034, a potent, selective, and orally bioavailable allosteric KRAS inhibitor
    Zhang, Yang W.
    Rominger, Dave
    Vo, Elizabeth Donohue
    Silva, Jillian M.
    Zhang, Yang J.
    Lee, Greg
    Micozzi, John
    Reid, Ben
    McDonough, Brooke
    Hospital, Audrey
    Luengo, Juan I.
    Pitt, Cameron
    Lin, Hong
    CANCER RESEARCH, 2023, 83 (08)
  • [2] Discovery and characterization of QTX3046, a potent, selective, and orally bioavailable non-covalent KRASG12D inhibitor
    Vo, Elizabeth Donohue
    Zhang, Yang W.
    Rominger, Dave
    Silva, Jillian M.
    Zhang, Yang J.
    Lee, Greg
    Micozzi, John
    Reid, Ben
    McDonough, Brooke
    Hospital, Audrey
    Luengo, Juan I.
    Lin, Hong
    Pitt, Cameron
    CANCER RESEARCH, 2023, 83 (08)
  • [3] Discovery of SHR1127, an orally bioavailable, highly potent and selective KRAS G12D inhibitor
    Li, Xin
    Shen, Feng
    Zhang, Limin
    Wang, Wei
    Kong, Luyao
    Bao, Yong
    Mao, Yuchang
    Wang, Zaiyong
    Lin, Sophie
    Zhang, Zhe
    Feng, Jun
    Hu, Min
    He, Feng
    CANCER RESEARCH, 2024, 84 (06)
  • [4] Preclinical characterization of LY3962673, an orally bioavailable, highly potent, and selective KRAS G12D inhibitor
    Iyer, Chandrasekar
    Li, Binghui
    Stewart, Trent R.
    Wang, Tao
    Capen, Andrew
    Cavitt, Rachel
    Anderson, Bryan D.
    Bocchinfuso, Wayne
    Zhao, Gaiying
    Rodriguez, Michael J.
    Carballares, Santiago
    Cooke, Andrew
    Bondi, Robert
    Burns, Lee
    Kelamangalath, Lakshmi
    Wallace, Ross
    Kolakowski, Gabrielle
    Henry, James R.
    Si, Chong
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [5] Discovery of INCB159020, an Orally Bioavailable KRAS G12D Inhibitor
    Ye, Qinda
    Shvartsbart, Artem
    Li, Zhenwu
    Gan, Pei
    Policarpo, Rocco L.
    Qi, Chao
    Roach, Jeremy J.
    Zhu, Wenyu
    Mccammant, Matthew S.
    Hu, Bin
    Li, Gencheng
    Yin, Haolin
    Carlsen, Peter
    Hoang, Gia
    Zhao, Le
    Susick, Robert
    Zhang, Fenglei
    Lai, Cheng-Tsung
    Hassani, Abdellah Allali
    Epling, Leslie B.
    Gallion, Alexandra
    Kurzeja-Lipinski, Kerri
    Gallagher, Karen
    Roman, Valerie
    Farren, Matthew R.
    Kong, Weixi
    Deller, Marc C.
    Zhang, Guofeng
    Covington, Maryanne
    Diamond, Sharon
    Kim, Sunkyu
    Yao, Wenqing
    Sokolsky, Alexander
    Wang, Xiaozhao
    JOURNAL OF MEDICINAL CHEMISTRY, 2025, 68 (02) : 1924 - 1939
  • [6] Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770
    Curtin, ML
    Florjancic, AS
    Heyman, HR
    Michaelides, MR
    Garland, RB
    Holms, JH
    Steinman, DH
    Dellaria, JF
    Gong, J
    Wada, CK
    Guo, Y
    Elmore, IB
    Tapang, P
    Albert, DH
    Magoc, TJ
    Marcotte, PA
    Bouska, JJ
    Goodfellow, CL
    Bauch, JL
    Marsch, KC
    Morgan, DW
    Davidsen, SK
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (12) : 1557 - 1560
  • [7] A first-in-class EGFR-directed KRAS G12V selective inhibitor
    Stanland, Lyla
    Huggins, Hayden
    Porrello, Alessandro
    Chareddy, Yogitha
    Azam, Salma
    Perry, Jillian
    Pallan, Pradeep
    Whately, Kristina
    Edatt, Lincy
    Fleming, Matthew
    Im, Jonah
    Gutierrez-Ford, Christina
    Simmons, Imani
    Jayaprakash, Vandanaa
    Sellers, Rani
    de la Cruz, Gabriela
    Wielgus, Albert
    Egli, Martin
    Bowers, Albert
    Pecot, Chad
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (11)
  • [8] INCB161734: A novel, potent, and orally bioavailable KRAS G12D selective inhibitor demonstrates antitumor activity in KRAS G12D mutant tumors
    Farren, Matthew R.
    Roman, Valerie
    Gallion, Alexandra
    Allali-Hassani, Abdellah
    Sokolsky, Alexander
    Kong, Weixi
    Smith, Amanda
    Wang, Hui
    Correa, Gina
    Deller, Marc
    Epling, Leslie B.
    Procak, Jessica
    Zhang, Guofeng
    Pecko, Katherine
    Kennedy, Keith
    Boer, Jason
    Kurzeja-Lipinski, Kerri
    Covington, Maryanne
    Chen, Kwang-Jong
    Wallower, Renee
    Rocha, Jennifer
    Pan, Rina
    Perry, Anthony
    Yuska, Brad
    Wang, Xiaozhao
    Macarron, Ricardo
    Kim, Sunkyu
    CANCER RESEARCH, 2024, 84 (06)
  • [9] Discovery of RGT-018: A Potent, Selective, and Orally Bioavailable SOS1 Inhibitor for KRAS-Driven Cancers
    Xiao, Fei
    Wang, Kailiang
    Wang, Xinjuan
    Li, Huijuan
    Hu, Zhilong
    Ren, Xiaoming
    Huang, Wei
    Feng, Teng
    Yao, Lili
    Lin, Jing
    Li, Chunlai
    Zhang, Zhuanzhuan
    Mei, Liufeng
    Zhu, Xiaotian
    Zhong, Wenge
    Xie, Zhi
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (12) : 1703 - 1716
  • [10] Discovery and Characterization of RGH-122, a Potent, Selective, and Orally Bioavailable V1a Receptor Antagonist
    Baska, Ferenc
    Bozo, Eva
    Szeleczky, Zsolt
    Szanto, Gabor
    Vukics, Krisztina
    Szakacs, Zoltan
    Domany-Kovacs, Katalin
    Kurko, Dalma
    Vass, Elemer
    Than, Marta
    Vastag, Monika
    Temesvari, Krisztina
    Levai, Sandor
    Halasz, Attila Sandor
    Kordas, Krisztina Szondine
    Roman, Viktor
    Greiner, Istvan
    Bata, Imre
    JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (01) : 643 - 673
123